Insmed Incorporated (INSM) Stock Analysis
Falling Knife setup
Healthcare · Biotechnology
Sell if holding. Momentum 3.0/10 is below the 5.0 floor at $135.83 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Leverage penalty (D/E 1.0): -0.5; Concentration risk — Product: ARIKAYCE and BRINSUPRI.
Insmed is a global biopharmaceutical company with two commercial products: ARIKAYCE for MAC lung disease (approved in US, Europe, Japan) and BRINSUPRI for non-cystic fibrosis bronchiectasis (approved US August 2025, EU November 2025), plus clinical programs in respiratory,... Read more
Sell if holding. Momentum 3.0/10 is below the 5.0 floor at $135.83 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Leverage penalty (D/E 1.0): -0.5; Concentration risk — Product: ARIKAYCE and BRINSUPRI. Chart setup: Death cross, below all MAs, RSI 25, MACD bearish. Score 5.1/10, moderate confidence.
Passes 5/7 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear). Fails on weak momentum and earnings proximity 7d<=7d. Suitability: moderate.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductARIKAYCE and BRINSUPRI10-K Item 1A: 'Our prospects are highly dependent on the success of our approved products, ARIKAYCE and BRINSUPRI.'
Material Events(8-K, last 90d)
- 2026-02-19Item 5.02LOWDirector David W.J. McGirr notified Insmed Board he will not stand for re-election at the 2026 Annual Meeting of Shareholders. He will continue serving as Board member and Audit Committee chair until the Annual Meeting. No disagreement with Company on any matter.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
4 floor-breakers·1 ceiling hit
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Priced at a premium — multiples above sector norms. Needs delivery on growth + margins to justify.static
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Momentum 3.0/10 is below the 5.0 floor at $135.83 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Leverage penalty (D/E 1.0): -0.5; Concentration risk — Product: ARIKAYCE and BRINSUPRI. Chart setup: Death cross, below all MAs, RSI 25, MACD bearish. Prior stop was $128.59. Score 5.1/10, moderate confidence.
Take-profit target: $191.43 (+40.8% upside). Prior stop was $128.59. Stop-loss: $128.59.
Concentration risk — Product: ARIKAYCE and BRINSUPRI; Leverage penalty (D/E 1.0): -0.5; Earnings in 7 days (event risk).
Insmed Incorporated trades at a P/E of N/A (forward 181.3). TrendMatrix value score: 3.0/10. Verdict: Sell.
26 analysts cover INSM with a consensus score of 4.3/5. Average price target: $213.
What does Insmed Incorporated do?Insmed is a global biopharmaceutical company with two commercial products: ARIKAYCE for MAC lung disease (approved in...
Insmed is a global biopharmaceutical company with two commercial products: ARIKAYCE for MAC lung disease (approved in US, Europe, Japan) and BRINSUPRI for non-cystic fibrosis bronchiectasis (approved US August 2025, EU November 2025), plus clinical programs in respiratory, immunology, and rare neurology. Revenue is generated primarily from ARIKAYCE and BRINSUPRI sales to specialty pharmacies and healthcare providers.